Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab

Annals of Pharmacotherapy

Volumn 43, Issue 7-8, 2009, Pages 1370-1373

  Shaikh, Aisha ^a   Wiisanen, Matthew E ^d   Gunderson, Heidi D ^b   Leung, Nelson ^c,d  

^a Wichita Nephrology Group   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d NONE

Author keywords

Bevacizumab; Capecitabine; Fanconi syndrome; Irinotecan

Indexed keywords

BEVACIZUMAB; CALCIUM CARBONATE; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LISINOPRIL; LOPERAMIDE; METOPROLOL; MEVINOLIN; ONDANSETRON; OXALIPLATIN; OXYCODONE; PANTOPRAZOLE; PARACETAMOL; POTASSIUM CHLORIDE; PROCHLORPERAZINE; SODIUM DIHYDROGEN PHOSPHATE;

ADJUVANT THERAPY; AGED; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COLON BIOPSY; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FEMALE; HEMICOLECTOMY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; FANCONI SYNDROME; FEMALE; FLUOROURACIL; HUMANS;

EID: 67651121848     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M120     Document Type: Article

References (29)

1. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003;41:292-309.
2. Morris RC Jr. Renal tubular acidosis. Mechanisms, classification and implications. N Engl J Med 1969;281:1405-1413
3. Lacy MQ, Gertz MA. Acquired Fanconi's syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am 1999;13: 1273-1280 (Pubitemid 30017400)
4. Finkel PN, Kronenberg K, Pesce AJ, Pollak VE, Pirani CL. Adult Fanconi syndrome, amyloidosis and marked kappa-light chain proteinuria. Nephron 1973;10:1-24.
5. Harrison JF, Blainey JD. Adult Fanconi syndrome with monoclonal abnormality of immunoglobulin light chain. J Clin Pathol 1967;20:42-48
6. Rao DS, Parfitt AM, Villanueva AR, Dorman PJ, Kleerekoper M. Hypophosphatemic osteomalacia and adult Fanconi syndrome due to lightchain nephropathy. Another form of oncogenous osteomalacia. Am J Med 1987;82:333-338 (Pubitemid 18131120)
7. Vertuno LL, Preuss HG, Argy WP Jr, Schreiner GE. Fanconi syndrome following homotransplantation. Arch Intern Med 1974;133:302-305
8. Smith GC, Balfe JW, Kooh SW. Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant 1995;10:543-545
9. Lande MB, Kim MS, Bartlett C, Guay-Woodford LM. Reversible Fanconi syndrome associated with valproate therapy. J Pediatr 1993;123: 320-322 (Pubitemid 23221121)
10. Negro A, Regolisti G, Perazzoli F, Davoli S, Sani C, Rossi E. Ifosfamide- induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient. Nephrol Dial Transplant 1998;13: 1547-1549 (Pubitemid 28254336)
11. Koch Nogueira PC, Hadj-Aissa A, Schell M, et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998;12:572-575 (Pubitemid 28408229)
12. Cachat F, Nenadov-Beck M, Guignard JP. Occurrence of an acute Fanconi syndrome following cisplatin chemotherapy. Med Pediatr Oncol 1998;31:40-41
13. Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999;32:93-96 (Pubitemid 29053004)
14. Garcia AA. Ifosfamide-induced Fanconi syndrome. Ann Pharmacother 1995;29:590-591
15. Montoliu J, Carrera M, Darnell A, Revert L. Lactic acidosis and Fanconi's syndrome due to degraded tetracycline. Br Med J (Clin Res Ed) 1981;283:1576-1577 (Pubitemid 12239411)
16. Gainza FJ, Minguela JI, Lampreabe I. Aminoglycoside-associated Fanconi's syndrome: an underrecognized entity. Nephron 1997;77:205-211
17. Crowther MA, Callaghan W, Hodsman AB, Mackie ID. Dideoxyinosine- associated nephrotoxicity. AIDS 1993;7:131-132
18. Vittecoq D, Dumitrescu L, Beaufils H, Deray G. Fanconi syndrome associated with cidofovir therapy (letter). Antimicrob Agents Chemother 1997;41:1846.
19. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245 (Pubitemid 11140804)
20. Butler HE Jr, Morgan JM, Smythe CM. Mercaptopurine and acquired tubular dysfunction in adult nephrosis. Arch Intern Med 1965;116:853-856
21. Debray FG, Merouani A, Lambert M, et al. Acute tubular dysfunction with Fanconi syndrome: a new manifestation of mitochondrial cytopathies. Am J Kidney Dis 2008;51:691-696
22. Roth KS, Carter BE, Higgins ES. Succinylacetone effects on renal tubular phosphate metabolism: a model for experimental renal Fanconi syndrome. Proc Soc Exp Biol Med 1991;196:428-431
23. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292 (Pubitemid 32366981)
24. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. [see comment]. J Clin Oncol 2001;19:4097-4106 (Pubitemid 33049527)
25. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996;23(suppl 3):34-41. (Pubitemid 26117270)
26. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434 (Pubitemid 36910021)
27. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(suppl 16):117-124
28. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65
29. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33(suppl 10):S26-34. (Pubitemid 44634007)